Fulgent Genetics Valuation
Is FLGT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FLGT?
Other financial metrics that can be useful for relative valuation.
|What is FLGT's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does FLGT's PE Ratio compare to its peers?
|FLGT PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
CCRN Cross Country Healthcare
ADUS Addus HomeCare
NRC National Research
FLGT Fulgent Genetics
Price-To-Earnings vs Peers: FLGT is good value based on its Price-To-Earnings Ratio (2.9x) compared to the peer average (27.4x).
Price to Earnings Ratio vs Industry
How does FLGT's PE Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Earnings vs Industry: FLGT is good value based on its Price-To-Earnings Ratio (2.9x) compared to the US Healthcare industry average (18.4x)
Price to Earnings Ratio vs Fair Ratio
What is FLGT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||2.9x|
|Fair PE Ratio||3.2x|
Price-To-Earnings vs Fair Ratio: FLGT is good value based on its Price-To-Earnings Ratio (2.9x) compared to the estimated Fair Price-To-Earnings Ratio (3.2x).
Share Price vs Fair Value
What is the Fair Price of FLGT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: FLGT ($37.92) is trading above our estimate of fair value ($8.88)
Significantly Below Fair Value: FLGT is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.